Hemophilia without prophylaxis: Assessment of joint range of

Hemophilia A and B: An Overview

Cureus, Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment

Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM), Journal of Patient-Reported Outcomes

Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial

PDF) Haemophilia and joint disease: pathophysiology, evaluation and management

Bleeding pattern, treatment, and outcome according to hemophilia type

Frontiers Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study - ScienceDirect

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B - ScienceDirect

Improvement in Joint Health Observed With Gene Therapy in Hemophilia A - Hematology Advisor

Hemophilia Nursing Care Planning and Management Study Guide - Nurseslabs

Early FVIII Prophylaxis Improves Long-Term Joint Outcomes in Severe Hemophilia A

Study: Early Diagnosis of Hemophilia Is Important Even in Mild Cases